JOSEPH D ROSENBLATT, MD
Osteopathic Medicine in Miami, FL

License number

Florida ME88673

Professional information

Dr. Joseph D Rosenblatt, Miami FL - MD (Doctor of Medicine)

Specialties:

Hematology, Medical Oncology, Oncology

Address:

Sylvester Comprehensive Cancer
1475 NW 12Th Ave, Miami 33136
(305) 243-1000 (Phone)

Certifications:

Hematology, 1990, Internal Medicine, 1983, Medical Oncology, 1985, Physical Medicine & Rehabilitation

Awards:

Healthgrades Honor Roll

Languages:

English, Spanish

Hospitals:

Sylvester Comprehensive Cancer
1475 NW 12Th Ave, Miami 33136
Mercy Hospital
3663 South Miami Ave, Miami 33133
Sylvester Comprehensive Cancer Center/UMHC
1475 West 12Th Ave, Miami 33136
University of Miami Hospital
1400 West 12Th Ave, Miami 33136

Education:

Medical School
David Geffen School Of Medicine At UCLA, University Of California, Los Angeles
Graduated: 1980
University Of California-Los Angeles
UCLA Affil Hosps
UCLA Med Center

Joseph David Rosenblatt, Miami FL

Specialties:

Internal Medicine, Medical Oncology, Hematology & Oncology, Hematology, Hematology

Work:

Sylvester Comprehensive Cancer
1475 NW 12Th Ave, Miami, FL 33136 Jackson Memorial Hospital
1611 NW 12Th Ave, Miami, FL 33136

Education:

University of California at Los Angeles (1980) Hematology & Oncology

Chief, Division Of Hem/Onc At Um/Sccc

Position:

Chief, Division of Hem/Onc at UM/SCCC

Location:

Miami/Fort Lauderdale Area

Industry:

Hospital & Health Care

Work:

UM/SCCC - Chief, Division of Hem/Onc

Antibody- Endostatin Fusion Protein And Its Variants

US Patent:

2011003, Feb 17, 2011

Filed:

Jun 26, 2008

Appl. No.:

12/665007

Inventors:

Seung-Uon Shin - Miami FL, US
Joseph David Rosenblatt - Miami FL, US
Sherie L. Morrison - Los Angeles CA, US

Assignee:

University of Miami - Miami FL

International Classification:

A61K 39/395, A61P 35/00, C07K 19/00, C07H 21/04, C12N 5/10

US Classification:

4241341, 5303873, 536 234, 435328

Abstract:

Chimeric molecules comprising endostatin and all or a portion of a tumor antigen specific binding molecule for use in treating tumors. The chimeric molecule, includes endostatin, endostatin mutants and variants and an antibody or aptamer specific for a desired tumor antigen. Methods of treating cancer comprise administering the chimeric fusion molecules.